巴瑞替尼治疗成人中重度特应性皮炎八项随机临床研究中疱疹病毒感染的综合分析
该研究整合了八项随机临床研究(六项双盲安慰剂对照试验和两项长期扩展研究)的数据,分析接受巴瑞替尼治疗的特应性皮炎成人患者中治疗期出现的单纯疱疹感染(包括疱疹性湿疹)和带状疱疹。结果显示单纯疱疹常见(8.9%),疱疹性湿疹发生率低(1.7%),带状疱疹罕见(2.1%)且无剂量依赖性增加。
要点
- 巴瑞替尼治疗患者中单纯疱疹报告率为8.9%,多数为轻中度(93.3%),仅2.2%导致永久停药。
- 疱疹性湿疹发生率低(1.7%),严重事件仅见于感染发生时疾病控制不佳(vIGA-AD评分≥3)的患者。
- 带状疱疹报告率2.1%,安慰剂对照期无剂量关系(2mg组IR=2.7,4mg组IR=0.0)。
核心结论
- 治疗期出现的单纯疱疹常见,而疱疹性湿疹不常见;多数疱疹性湿疹局限且累及小面积体表面积,并与疾病控制不佳相关;带状疱疹在安慰剂对照数据集中罕见,且频率无剂量依赖性增加。
研究设计与样本
- 研究整合了六项双盲、随机、安慰剂对照试验和两项长期扩展研究的数据,分析集包括安慰剂对照集、2-4mg巴瑞替尼扩展集和全部巴瑞替尼特应性皮炎集。
- 全部巴瑞替尼特应性皮炎集共纳入2531例患者,累计2247人年。
主要发现
- 在全部巴瑞替尼特应性皮炎集中,单纯疱疹报告于8.9%的患者(n=224;发生率=10.3/100人年),其中93.3%为轻中度,2.2%导致永久停药,51.3%表现为口腔/口周单纯疱疹。
- 疱疹性湿疹在全部巴瑞替尼特应性皮炎集中发生率为1.7%(n=43;发生率=2.0/100人年),在安慰剂、2mg巴瑞替尼和4mg巴瑞替尼组分别报告于0.5%、0.2%和1.4%的患者。
- 在全部巴瑞替尼特应性皮炎集中,79.1%的疱疹性湿疹事件被研究者评为轻中度,74.2%累及≤2%体表面积,88.4%为单发事件;严重疱疹性湿疹(n=11)仅发生于感染发生时疾病控制不佳(vIGA-AD评分≥3)的患者。
- 带状疱疹报告于2.1%的巴瑞替尼治疗患者(n=53;发生率=2.3/100人年),安慰剂对照期2mg组发生率=2.7、4mg组发生率=0.0,扩展数据集2mg组发生率=3.7、4mg组发生率=1.7。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is associated with an increased risk for viral infections including those caused by herpes simplex virus and varicella zoster virus. OBJECTIVES: This study examined treatment-emergent (TE) herpes simplex infection including eczema herpeticum (EH), and herpes zoster (HZ), in adult patients with AD receiving ≥1 dose of baricitinib (BARI), an oral selective inhibitor of Janus kinase 1/2. METHODS: We evaluated data from six double-blinded, randomized, placebo-controlled (PC) trials and two long-term extension studies, within three analysis sets: PC, 2-4-mg BARI extended and All-BARI-AD. Frequency, incidence rate (IR)/100 person-years (PYs) and clinical characteristics of TE-herpes simplex, EH and HZ were reported. RESULTS: In the All-BARI-AD dataset (n = 2531; 2247 PYs), herpes simplex was reported in 8.9% of patients (n = 224; IR = 10.3). Most herpes simplex events were rated as mild or moderate (93.3%), rarely led to permanent discontinuation (2.2%) and presented mostly as oral/perioral herpes simplex (51.3%). TE-EH occurred at a low frequency (All-BARI-AD 1.7% n = 43; IR = 2.0) and were reported in 0.5%, 0.2% and 1.4% of patients receiving placebo, 2-mg or 4-mg BARI respectively. In the All-BARI-AD dataset, most events were investigator-rated as mild/moderate (79.1%), affected ≤2% of the body surface area (74.2%) and occurred as single events (88.4%). Serious TE-EH (n = 11) occurred exclusively in patients with poor disease control (vIGA-AD™ score ≥3) at infection onset. TE-HZ was reported in 2.1% of BARI patients (n = 53; IR = 2.3), without a dose relationship during the PC period (IR = 2.7 and IR = 0.0) or the extended dataset (IR = 3.7 and IR = 1.7) for 2- or 4-mg BARI respectively. CONCLUSIONS: TE-herpes simplex was common, while occurrence of EH was uncommon. Most events of EH were localized with involvement of a small BSA and were linked to poor disease control. Events of HZ were rare in the PC dataset and without a dose dependent increase in frequency.
引用
- Werfel T, Irvine AD, Bangert C, et al. An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022. PMID: 35490395. doi:10.1111/jdv.18193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。